Position of the Transparency Council – Libtayo (cemiplimab)

At its meeting on 25 November 2024, the Transparency Council adopted position No. 131/2024 on the evaluation of the drug Libtayo (cemiplimab) in the framework of the drug programme B.159 ‘Treatment of patients with cervical cancer (ICD-10: C53)’

Publication of the position >>